- Home
- MEIP vs FLUX Comparison
MEIP vs FLUX Comparison
Compare MEIP & FLUX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MEIP
- FLUX
- Stock Information
- Founded
- MEIP 2000
- FLUX N/A
- Country
- MEIP United States
- FLUX United States
- Employees
- MEIP N/A
- FLUX N/A
- Industry
- MEIP Biotechnology: Pharmaceutical Preparations
- FLUX Industrial Machinery/Components
- Sector
- MEIP Health Care
- FLUX Miscellaneous
- Exchange
- MEIP Nasdaq
- FLUX Nasdaq
- Market Cap
- MEIP 17.1M
- FLUX 20.2M
- IPO Year
- MEIP 2003
- FLUX N/A
- Fundamental
- Price
- MEIP $1.98
- FLUX $1.70
- Analyst Decision
- MEIP Hold
- FLUX Strong Buy
- Analyst Count
- MEIP 1
- FLUX 3
- Target Price
- MEIP N/A
- FLUX $6.33
- AVG Volume (30 Days)
- MEIP 11.6K
- FLUX 33.2K
- Earning Date
- MEIP 05-08-2025
- FLUX 03-20-2025
- Dividend Yield
- MEIP N/A
- FLUX N/A
- EPS Growth
- MEIP N/A
- FLUX N/A
- EPS
- MEIP N/A
- FLUX N/A
- Revenue
- MEIP N/A
- FLUX $60,789,000.00
- Revenue This Year
- MEIP N/A
- FLUX $11.85
- Revenue Next Year
- MEIP N/A
- FLUX $13.10
- P/E Ratio
- MEIP N/A
- FLUX N/A
- Revenue Growth
- MEIP 33.76
- FLUX N/A
- 52 Week Low
- MEIP $1.46
- FLUX $1.15
- 52 Week High
- MEIP $4.10
- FLUX $5.05
- Technical
- Relative Strength Index (RSI)
- MEIP 40.20
- FLUX 57.01
- Support Level
- MEIP $1.86
- FLUX $1.38
- Resistance Level
- MEIP $2.35
- FLUX $1.50
- Average True Range (ATR)
- MEIP 0.16
- FLUX 0.14
- MACD
- MEIP 0.02
- FLUX 0.00
- Stochastic Oscillator
- MEIP 68.42
- FLUX 97.52
About MEIP MEI Pharma Inc.
MEI Pharma Inc is focused on the clinical development of novel therapies for cancer. The company's clinical drug candidate includes Pracinostat, an orally available histone deacetylase inhibitor for the treatment of patients with acute myeloid leukemia and myelodysplastic syndrome. Its clinical development portfolio also includes Zandelisib, an oral inhibitor of phosphatidylinositide 3-kinase delta for the treatment of patients with recurrent chronic lymphocytic leukemia or follicular non-Hodgkin's lymphoma; and ME-344, an isoflavone-based mitochondrial inhibitor for the treatment of HER2-negative breast cancer and Pracinostat, an oral histone deacetylase inhibitor. Geographically, all the business activities function through the region of the United States.
About FLUX Flux Power Holdings Inc.
Flux Power Holdings Inc design, develop, manufacture, and sell a portfolio of lithium-ion energy storage solutions for electrification of a range of industrial commercial sectors which include material handling, airport ground support equipment (GSE), and other commercial and industrial applications. It offers a high-power battery cell management system(BMS). The company's BMS provides three functions to its battery systems which include Cell Balancing, Monitoring, and Error Reporting.